On October 10, 2025, Tempus AI announced it was selected by the Advanced Research Projects Agency for Health (ARPA‑H) to provide testing and contract research organization (CRO) services for the ADAPT program, a federal initiative focused on adaptive precision cancer therapy for non‑small cell lung, breast, and colorectal cancers.
Tempus will supply its AI‑enabled diagnostics portfolio—including the xE, xR, xF+, and xM assays—as well as its Compass CRO platform to manage trial operations across participating sites. The partnership leverages Tempus’s multimodal data integration capabilities to collect and harmonize study data on behalf of the program.
The contract positions Tempus as a key partner in a government‑backed research effort aimed at developing adaptive treatment strategies, potentially expanding its market reach and reinforcing its AI‑driven diagnostics pipeline. The selection underscores the agency’s confidence in Tempus’s technology and could drive future revenue growth.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.